Binosto® (buffered soluble alendronate 70mg) is indicated for the treatment of osteoporosis.
Binosto® is an effervescent tablet containing alendronic acid, offering a novel treatment option for osteoporosis; it reduces the risk of vertebral and hip fractures. Binosto® is formulated to be dissolved in water yielding a buffered oral solution (of pH 4.8 – 5.4). This formulation facilitates delivery to the stomach and thus reduces the potential for local and oesophageal irritation.
Europe / UK: Treatment of osteoporosis in postmenopausal women. Binosto® 70 mg reduces the risk of vertebral and hip fractures.3
Switzerland: Binosto® is indicated for the treatment of osteoporosis in postmenopausal women and men.2
United States: Treatment of osteoporosis in postmenopausal women. Binosto® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto® is indicated for treatment to increase bone mass in men with osteoporosis.
Visit www.binosto.com for U.S. approved prescribing information.
Disclaimer: Please refer to the official prescribing information in your country regarding the indications, contraindications and warnings.
Binosto® is commercialized in the United States and in selected countries in Europe, Middle East and Asia.
EffRx seeks to further expand Binosto’s footprint to countries where the product is not yet marketed, particularly in North Africa and Latin America.
1. Binosto Summary of Product Characteristics. June 2021;
3. Binosto Summary of Product Characteristics. June 2021 and www.medicines.org.uk/emc/product/7113/smpc#gref
